Alembic Pharmaceuticals share news and announcements
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Last close ₹760.10down ₹21.20 (2.71%)BSE ₹758.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.
52-week range of traded prices to 23 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,941 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 21.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,20,84752.2% delivered
Alembic Pharmaceuticals shareholder meetings
49 filed, newest first.
Aug 2026
Jul 2026
Mar 2026
Feb 2026
27 Feb · Meeting
Aug 2025
Jun 2025
Mar 2025
Feb 2025
12 Feb · Meeting
Jul 2024
22 Jul · Meeting
Jun 2024
May 2024
Apr 2024
9 Apr · Meeting
Aug 2023
Jun 2023
Nov 2022
Sep 2022
Mar 2022
Feb 2022
11 Feb · Meeting
Jul 2021
Jun 2021
Jul 2020
Jul 2019
Jun 2019
Jul 2018
Jun 2018
Jul 2017
Jun 2017
Mar 2017
15 Mar · Meeting
Feb 2017
Jul 2016
Jun 2016
Sep 2015
Jun 2015
Aug 2014
Jun 2014
3 Jun · Meeting
Company has fixed Book Closure from July 21, 2014 to July 28, 2014 (both days inclusive) for the purpose of Annual General Meeting to be held on July 28, 2014 and payment of Dividend for the F.Y. 2013-14.
Aug 2013
Jun 2013
5 Jun · Meeting
Register of Members and Share Transfer Books of the Company shall remain closed from July 31, 2013 to August 7, 2013 (both days inclusive) for the purpose of Annual General Meeting to be held on August 07, 2013 and payment of Dividend for the F.Y. 2012-13.
Jul 2012
4 Jul · Meeting
Annual General Meeting of the Company shall be held on August 09, 2012. Further, the Register of Members and Share Transfer Books of the Company shall remain closed from August 02, 2012 to August 09, 2012 (both days inclusive) for the purpose of declaration of dividend and Annual General Meeting of the Company for the F.Y. 2011-12.